Chief Medical Officer

SJP Biotec GmbH is a clinical-stage precision oncology company pioneering a first-in-class Selective Translation Regulatory Inhibitor (STRI) platform powered to overcome treatment resistance in refractory cancers. Founded in 2024, SJP targets RAS-driven, hormone-receptor-positive, and immune-refractory tumors with a novel pipeline of small molecules developed in our lab and ready to proceed with regulatory-grade trials.
Backed by a Scientific Advisory Board that includes world-leading authorities in RAS and breast cancer biology, and immuno-oncology, SJP has established clinical partnerships with leading medical centers world-wide including UCSF, NCI, MD Anderson, Baylor College of Medicine, MSKCC, and McGill, to name a few.

The Opportunity
This is a stimulating and unique opportunity to join a scientifically exceptional, capital-efficient biotech company doing groundbreaking work at a pivotal inflection point. The CMO/SVP of Clinical Development will serve as the company's most senior clinical leader, responsible for designing and executing a multi-indication clinical development strategy across one of the most compelling areas in the current oncology drug development field - RAS/eIF4A/translation-pathway inhibition.

Key Responsibilities

• Translate and deliver key directives from the board and senior management, and serve as the clinical face of the company.
• Lead and manage all clinical development activities across the SJP portfolio
• Design Phase 2 and 3 clinical protocols and oversee CTA/IND submissions to BfArM, FDA, and EMA
• Develop and implement biomarker-driven patient selection strategies
• Build and manage relationships with leading academic and clinical sites across Germany, the EU, and the US
• Oversee Investigator Initiated Trials and partnerships, providing scientific leadership and interactions as required
• Lead regulatory strategy, developing approaches for Fast Track Designation, Breakthrough Therapy Designation, and accelerated approval pathways as applicable
• Support pharmaceutical partnering activities - prepare clinical data packages and respond to due diligence for potential licensing and out-licensing transactions
• Build out of the clinical development and operations function, including recruitment of CRAs, medical monitors, and data management staff
• Present clinical data at major oncology congresses and to key opinion leaders
• Interact with potential investors and financial institutions to raise capital when needed.

Candidate Profile
Essential Qualifications

• MD, with specialization in medical oncology and hematology
• 10+ years of experience in oncology clinical development within pharma, biotech, or CRO settings with hands-on clinical trial leadership
• Demonstrated track record of successful IND/CTA submissions
• Leadership of interactions with FDA and/or EMA
• Experience with biomarker-driven trial design and companion diagnostic development
• Expertise in breast cancer, NSCLC, and KRAS-mutant tumor biology
• Strong understanding of the competitive treatment landscape in clinical oncology
• Proven ability to manage investigator-initiated trials and academic site partnerships
• Strong scientific publication and/or congress presentation record in clinical oncology
• Excellent presentation skills
• Emphasizing teamwork and leading a team of experts in their fields

Highly Desired (But not required)

• Experience with RAS/KRAS biology, MAPK pathway inhibitors, or translation-pathway therapeutics
• PhD in an associated area of cancer biology
• Experience with basket trial design and multi-cohort oncology studies
• Background in immuno-oncology combinations, particularly in checkpoint inhibitor resistance settings
• Prior involvement in pharma partnering or licensing due diligence from the biotech side
• Working knowledge of German regulatory frameworks alongside international GCP/ICH guidelines
• Established professional network at leading cancer centres